Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24823954 | 0.83 | TYK2 (0.34) | CHRM2CHRM3PIK3CDPIK3CAPIK3CG | |
| SCHEMBL30079392 | 0.83 | TYK2 (0.34) | CHRM2CHRM3PIK3CDPIK3CAPIK3CG | |
| SCHEMBL24823945 | 0.75 | CHRM2 (0.34) | CHRM2CHRM3FYN | |
| SCHEMBL24823668 | 0.71 | CHRM2 (0.35) | CHRM2CHRM3MEN1MAPTKMT2A | |
| SCHEMBL24823030 | 0.70 | CHRM2 (0.36) | CHRM2CHRM3PIK3CDPIK3CAPIK3CG | |
| SCHEMBL24823515 | 0.68 | TYK2 (0.34) | CHRM2CHRM3PIK3CDPIK3CAPIK3CG | |
| SCHEMBL24823950 | 0.66 | CHRM2 (0.35) | CHRM2CHRM3 | |
| SCHEMBL24823959 | 0.63 | HSD17B10 (0.34) | TLR8FYNMEN1POLBKMT2A | |
| SCHEMBL30079422 | 0.63 | HSD17B10 (0.34) | TLR8FYNMEN1POLBKMT2A | |
| SCHEMBL13510718 | 0.62 | CASP3 (0.43) | CHRM2CHRM3TLR8MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4337655-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022241171-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-11-17 | — | — | WO | disclosed |